Yueqi Wang, Mingxing Hu, Junjie Wu, Lili Pan, Huijun Zhou, Li Li, Weihong Kuang, Yongmei Xie* and Wei Chen*,
{"title":"Discovery of Novel KuE PSMA PET Tracers through Structure Fine-Tuning and Direct Photocatalyzed 18F-Deoxyfluorination","authors":"Yueqi Wang, Mingxing Hu, Junjie Wu, Lili Pan, Huijun Zhou, Li Li, Weihong Kuang, Yongmei Xie* and Wei Chen*, ","doi":"10.1021/acs.jmedchem.5c00741","DOIUrl":null,"url":null,"abstract":"<p >Prostate-specific membrane antigen (PSMA) PET imaging has been recognized as an effective modality for early and accurate prostate cancer (PCa) diagnosis. While the <sup>18</sup>F-labeled PSMA tracer was initially approved for clinical use, the structure–activity relationship (SAR) has been underexplored due to limited accessibility of the tracers. Herein, we designed and synthesized a group of PSMA PET tracers through structure-based meticulous optimization for potential interactions at the amphipathic S1 site. Notably, the <sup>18</sup>F-fluorinated electron-neutral and -rich aryl moiety instead was incorporated into the KuE motif through direct photocatalyzed <sup>18</sup>F-deoxyfluorination. The preferred [<sup>18</sup>F]<b>1c</b> (SUV<sub>max</sub> = 11.40 ± 1.75) demonstrated significantly superior tumor uptake over the clinically used [<sup>18</sup>F]<b>DCFPyL</b> (SUV<sub>max</sub> = 1.49 ± 0.31) and [<sup>68</sup>Ga]<b>PSMA-11</b> (SUV<sub>max</sub> = 4.2 ± 0.35) in LNCaP mice model and exhibited favorable metabolic properties. Moreover, the [<sup>18</sup>F]<b>1c</b> was successfully produced on a commercial autosynthesis module and further evaluated on a rhesus macaque, which holds great potential for clinical transformation of PCa diagnosis.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 14","pages":"14594–14608"},"PeriodicalIF":6.8000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00741","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate-specific membrane antigen (PSMA) PET imaging has been recognized as an effective modality for early and accurate prostate cancer (PCa) diagnosis. While the 18F-labeled PSMA tracer was initially approved for clinical use, the structure–activity relationship (SAR) has been underexplored due to limited accessibility of the tracers. Herein, we designed and synthesized a group of PSMA PET tracers through structure-based meticulous optimization for potential interactions at the amphipathic S1 site. Notably, the 18F-fluorinated electron-neutral and -rich aryl moiety instead was incorporated into the KuE motif through direct photocatalyzed 18F-deoxyfluorination. The preferred [18F]1c (SUVmax = 11.40 ± 1.75) demonstrated significantly superior tumor uptake over the clinically used [18F]DCFPyL (SUVmax = 1.49 ± 0.31) and [68Ga]PSMA-11 (SUVmax = 4.2 ± 0.35) in LNCaP mice model and exhibited favorable metabolic properties. Moreover, the [18F]1c was successfully produced on a commercial autosynthesis module and further evaluated on a rhesus macaque, which holds great potential for clinical transformation of PCa diagnosis.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.